ALS Testing Through Home-based Outcome Measures

Amyotrophic Lateral Sclerosis Clinical Trial

— ALS AT HOME  

Official title:

ALS Testing Through Home-based Outcome Measures (ALS AT HOME)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03016897
• Other study ID #: BNI_ALS_001
• Status: Completed
• Start date: February 22, 2017
• Est. completion date: September 30, 2019

Study information

• Verified date: February 2023
• Source: Barrow Neurological Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

ALS AT HOME is a single-center study of up to 150 participants being done to determine the extent to which frequent sampling can improve the qualities of outcome measures collected at home by study participants.

Description:

ALS AT HOME is a single-center study of up to 150 participants being done to determine the extent to which frequent sampling can improve the qualities of outcome measures collected at home by study participants.

The objectives of this study are to

1. assess the extent to which frequent sampling can reduce variability for the following outcome measures in ALS patients: ALSFRS-R, quantitative hand grip, pulmonary function, EIM in 4 extremities, and actigraphy and voice/speech tracking;

2. assess the compliance of ALS patients in obtained outcome measures at home over the course of 9 months;

3. directly compare outcome measures collected by patients with measurements obtained at study sites at less frequent intervals by co-enrolling 50 patients participating in the Answer ALS study; and

4. provide information to Answer ALS to more fully characterize patients in that study.

The study proposed here will assess the extent to which reducing variability of measurement through frequent sampling can reduce both sample size and duration of clinical trials, provide a first-of-its-kind detailed assessment of disease progression, and evaluate an entirely new paradigm for patient participation in such trials without the need to be geographically yoked to a clinical study center. An important component of this proposal is to jointly recruit 50 patients who also participate in the Answer ALS study that intends to generate 1000 IP cell lines from patients who receive ongoing assessment at 5 clinical sites. The 100 participants that will be co-enrolled in Answer ALS and ALS AT HOME will perform outcome measures at home in addition to having outcome measures performed at clinic sites through Answer ALS participation. Therefore, the investigators will be able to directly assess how the measures obtained by patients at home relate to those obtained by a trained evaluator at a study center using standard metrics. The investigators will also provide all data generated at home to the Answer ALS investigators, further increasing the phenotypic data available for that project.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 144
• Est. completion date: September 30, 2019
• Est. primary completion date: June 28, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• male or female, age 18 to 85 years old,

• ownership of a Smart Device (phone, tablet, etc) with Bluetooth capabilities,

• continuous internet access at home,

• willing and able to provide informed consent in compliance with the regulatory requirements through a web based interface,

• definite, Probable, or Possible ALS by modified El Escorial criteria, as documented by medical records, with duration from diagnosis 60 months or less, and

• for the 50 participants in Group 2, participation in the Answer ALS study.

Exclusion Criteria:

• diagnosed and actively undergoing treatment for cancer, heart failure, end stage renal disease, or another significant medical condition deemed by the PI to likely affect the participant's ability to comply with the protocol,

• unwilling or unable to comply with the requirements of this protocol, including the presence of any condition (physical, mental, or social) that is likely to affect the participant's ability to comply with the protocol,

• any other reasons that, in the opinion of the PI, the candidate is determined to be unsuitable for entry into the study.

• Healthy volunteers who have family members with ALS

Related Conditions & MeSH terms

• Amyotrophic Lateral Sclerosis
• Motor Neuron Disease

Intervention

Other:
• Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter
Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter

Locations

Country	Name	City	State
United States	Barrow Neurological Institute	Phoenix	Arizona

Sponsors (2)

Lead Sponsor	Collaborator
Jeremy Shefner	Beth Israel Deaconess Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Pulmonary Function	Respirometer	Daily for the first 3 months; for the subsequent 6 months measures will be obtained twice weekly
Primary	Change in Quantitative Hand Grip	Digital Handgrip Meter	Daily for the first 3 months; for the subsequent 6 months measures will be obtained twice weekly
Primary	Change in Electrical Impedance Myography (EIM) Measurements	Skulpt Chisel	Daily for the first 3 months; for the subsequent 6 months measures will be obtained twice weekly
Primary	Change in Actigraphy	Activity Band	Daily for the first 3 months; for the subsequent 6 months measures will be obtained twice weekly
Primary	ALSFRS-R	Questionnaire	Weekly up to 9 months
Primary	Change in Patient-reported Experience measures (PREMs)	Questionnaire	At Week 1, and then at 3, 6, and 9 months
Primary	Adverse Events	Questionnaire	Monthly up to 9 months
Primary	Change in Voice/Speech Tracking	Smartphone application	Daily for the first 3 months; for the subsequent 6 months measures will be obtained twice weekly